

1 **Vascular Cutaneous Manifestations of COVID and RNA Viral Pathogens: a systematic**
2 **review**

3
4 Jamie L. Karch,¹ Chiamaka L. Okorie,¹ Mayra B.C. Maymone,² Melissa Laughter³ and Neelam
5 A. Vashi^{4,5}

6
7 ¹Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USA

8 ²Department of Dermatology, The Warren Alpert Medical School, Brown University,
9 Providence, RI, USA

10 ³Department of Dermatology, New York University, New York, NY, USA

11 ⁴Department of Dermatology, Boston University School of Medicine, Boston, MA, USA

12 ⁵Department of Dermatology, US Department of Veteran Affairs, Boston Health Care System,
13 Boston, MA, USA

14
15 **Corresponding author:** Jamie L. Karch

16 **Email:** Jamie.L.Karch.med@dartmouth.edu

17
18 **Funding sources:** This research received no specific grant from any funding agency in the
19 public, commercial, or not-for-profit sectors.

20 **Conflicts of interest:** None to declare.

21 **Data availability:** The data underlying this article will be shared on reasonable request to the
22 corresponding author.

23 **Ethics statement:** Not applicable.

24
25 **Learning Points**

- 26 • COVID-19 infections can manifest with various skin findings and are categorized as
27 either inflammatory or vasculitic. These include a spectrum of rashes such as
28 erythematous maculopapular/morbilliform rashes, petechial eruptions, urticarial lesions,
29 chilblains-like rashes, papulovesicular eruptions, and livedo retiform rashes.

- 1 • SARS-CoV-2, Rubella, Influenza, Dengue, Coxsackie, and Echovirus, amongst others,
2 exhibit varying skin manifestations. However, not all RNA virus families have been
3 linked to vascular cutaneous pathology.
- 4 • COVID-19 and COVID-19 vaccinations have been implicated in the reactivation of other
5 viruses, such as HHV-6/7, VZV, EBV, and HZ. This reactivation is believed to be driven
6 by the synergistic effects of elevated cytokines, particularly TH17 and IL-17, which
7 could account for the increased susceptibility to herpes virus reactivation among COVID-
8 19 patients. Future therapeutic strategies may investigate IL-17 signaling modulation as a
9 potential treatment approach.
- 10 • Cutaneous eruptions with vascular involvement, such as the distinctive purple-red acral
11 vasculopathy rash resembling chilblains lesions, are frequently observed with SARS-
12 CoV-2 infections and referred to as "COVID toe." These chilblain-like lesions can serve
13 as a sole skin manifestation of SARS-CoV-2 exposure, even when patients test negative.
- 14 • While the presentation of cutaneous symptoms may differ, most skin pathology stems
15 from diverse inflammatory responses characterized by heightened proinflammatory
16 markers and cytokine storms. This may explain the prolonged onset of vascular
17 symptoms observed in COVID-19, Influenza, and Chikungunya.
- 18 • Enhancing our understanding of the mechanism behind vascular cutaneous
19 manifestations of viral infections is essential for improving the clinical identification,
20 diagnosis, and management of RNA viral-related dermatological symptoms.

21 **Abstract**

23 **Background.** COVID-19, the widely recognized and highly contagious respiratory tract
24 infection, has had a substantial impact on the field of dermatology since its emergence in 2019.

1 Various skin-related symptoms have been reported in COVID-infected patients, most notably the
2 distinctive purple-red acral rash resembling chilblain lesions, commonly referred to as "COVID
3 toe." COVID-19 is classified within the viral RNA family category, and similarly, skin-related
4 symptoms have been observed in connection with other RNA viruses.

5 **Aim.** This review aims to explore the relationship between RNA viruses and their associated
6 vascular cutaneous manifestations in comparison to those observed in SARS-CoV-2 infected
7 patients.

8 **Methods.** A systematic literature review was conducted using the PubMed database and MeSh
9 terms regarding RNA viruses and related skin manifestations.

10 **Results.** A total of 3,994 patients diagnosed with COVID-19 presenting with skin rashes were
11 observed. Chilblain-like lesions (CLL) were most frequently observed (30.2%), followed by
12 erythematous maculopapular/morbilliform rashes (9.1%) and urticarial rashes (4.7%). Out of
13 8,362 patients diagnosed with RNA viruses, more than half of the skin findings reported were
14 erythematous/maculopapular/morbilliform rashes (52.3%), followed by unspecified rashes
15 (11.3%) and purpuric rashes (10.6%).

16 **Conclusion.** When comparing RNA viral infections to COVID-19 cases, we observed
17 similarities in reported skin manifestations and their presumed pathways, with many implicated
18 in the pro-inflammatory response. Due to the wide range of cutaneous symptoms associated with
19 RNA viruses and our current limited understanding of their underlying mechanisms, additional
20 research is warranted to investigate the pathology behind viral-induced skin lesions.

1 Introduction

2 Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a
3 ribonucleic acid (RNA) virus known as COVID-19, quickly spread globally, leading to its
4 declaration as a global pandemic.^{1,2} Spread via respiratory droplets, classic clinical
5 manifestations include fever, dry cough, diarrhea, shortness of breath, fatigue, and loss of taste or
6 smell. Reported clinical consequences have substantially impacted nearly every medical
7 specialty, including dermatology.^{3,4} Cutaneous manifestations of COVID-19 have been
8 categorized into two groups: those resulting from inflammation, like maculopapular and
9 papulovesicular eruptions, and those of a vascular origin, including pseudo-chilblain or chilblain-
10 like lesions, petechiae, and purpura.⁵⁻⁸

11 Cutaneous vascular complications stemming from SARS-CoV-2 infections have been
12 increasingly reported.⁹ One of the most prominent examples is the emergence of erythematous,
13 pruritic, and occasionally painful acral lesions resembling chilblain lesions, referred to as
14 “COVID or pernio toes.”^{10,11} SARS-CoV-2 has also been associated with other vascular
15 sequelae, such as the re-ulceration of infantile hemangiomas.¹²

16 Vascular skin findings observed in the context of COVID-19 prompt further investigation into
17 reported vascular cutaneous manifestations of other RNA viruses. The primary objective of this
18 review is to provide a comprehensive analysis of cutaneous symptoms associated with RNA
19 viruses, with emphasis on lesions with vascular involvement compared to those seen in patients
20 with SARS-CoV-2 infections. Our goal is to identify comparable morphological patterns to assist
21 in characterizing and depicting clinical presentations and pathology related to cutaneous viral
22 infections.

1 **Methods**

2 An electronic literature search was conducted on the PubMed (NLM) database from their
3 inception to September 30, 2022, using MeSh (Medical Subject Headings) terms. The MeSH
4 terms incorporated keywords and subject headings related to RNA viral families (Influenza,
5 Reovirus, Picornavirus, Hepevirus, Hepatitis Delta Virus, Norovirus, Flavivirus, Togavirus,
6 Retrovirus, Paramyxovirus, Rhabdovirus, Filovirus, Arenavirus, and Bunyavirus), in conjunction
7 with specific vascular cutaneous symptoms: chilblains, purpura, petechiae, thrombosis,
8 coagulopathy, retiform, skin necrosis, livedoid, ecchymosis, disseminated intravascular
9 coagulopathy (DIC), thrombotic thrombocytopenia purpura (TTP), hemolytic uremia syndrome
10 (HUS), and vasculitis.

11 Two authors (JLK and CLO) independently evaluated titles, abstracts, and full-text content from
12 the identified records (Figure 1). Discrepancies were resolved through discussion to reach a
13 consensus. Duplicated articles or those unrelated to cutaneous manifestations were excluded.
14 Literature reviews without case studies, articles focusing on fundamental science, histology,
15 pathophysiology, therapeutic strategies, vaccines, and animal studies were also disregarded.
16 Articles that focused on thrombotic symptoms such as deep vein thrombosis (DVT) and
17 pulmonary embolism (PE) without substantial skin-related findings were eliminated. Articles not
18 in English and those unable to be accessed were also excluded. Using Microsoft Excel, data was
19 extracted from the final set of included articles. The count of reported patients included those
20 with confirmed viral diagnoses and skin-related symptoms. Instances of rashes lacking detailed
21 descriptions or possessing unclear characterizations were categorized as unspecified rashes.

22

1 Results

2 A total of 92 articles were included in this review: 49 articles regarding RNA viruses, and 43
3 regarding COVID-19. Twenty-six case studies, 60 case cohort/case control studies, and 6 cross
4 sectional reviews included for analysis. The most frequently observed lesions chilblain like
5 lesions (30.2%), followed by erythematous maculopapular/morbilliform rashes (9.1%), urticarial
6 rashes (4.7%), papulovesicular rashes (3.7%), and livedo reticularis/racemose (3.5%) (Table 1).
7 Other reported manifestations included oral ulcers, erythema multiforme, and pityriasis rosea.

8 Eight RNA viral families were included in the final analysis: Coronaviridae, Orthomyxoviridae,
9 Picornaviridae, Flaviviridae, Togaviridae, Retroviridae, Paramyxoviridae, and Bunyaviridae
10 (Table 2). Reoviridae, Hepeviridae, Hepadnaviridae, Rhabdoviridae, Noroviridae, Filoviridae,
11 and Arenaviridae did not produce any studies related to cutaneous vascular phenomena and thus
12 were excluded. Among all the included families, Togaviridae yielded the highest number of
13 studies (58.7%), followed by Flaviviridae (21.2%), and Bunyaviridae (7.8%).

14 A total of 8,362 patients diagnosed with RNA viruses were included in this study. The most
15 prevalent skin finding reported among RNA viral infections was an
16 erythematous/maculopapular/morbilliform inflammatory rash, accounting for 52.3% of the cases.
17 This was followed by unspecified rashes (11.3%) and petechial/purpuric vasculitic rashes
18 (10.6%). Among the 4,913 patients who contracted Togaviridae, Rubella was the most prevalent
19 pathogen linked to skin findings (89.3%). In cases involving Togaviridae, primary observations
20 included maculopapular/morbilliform inflammatory rashes (93.8%), and vasculitic
21 manifestations like petechiae and purpura were in the minority (0.4%).

1 Significant skin findings for Flaviviridae were mainly associated with Dengue and encompassed
2 widespread vasculitic petechiae and purpura (34.5%), and unspecified rashes (30.2%). In
3 Bunyaviridae, petechiae/vasculitic symptoms were most commonly reported (29.9%), alongside
4 unspecified rashes (7.7%). Retroviridae was frequently associated with vasculitic cutaneous
5 symptoms (52.3%); erythematous/maculopapular/morbilliform rashes were a minority (11.5%).
6 Paramyxoviridae was dominated by petechiae/vasculitic symptoms (75%). Orthomyxoviridae
7 (Influenza cases) were linked with petechial/vasculitic symptoms (7.7%),
8 maculopapular/morbilliform/erythematous rashes (1.0%), and oral ulcers (1.0%). Patients
9 infected with Picornaviridae (Coxsackie and Echovirus) reported oral ulcers (34.6%) and
10 papulovesicular ulcers (5.3%).

12 **Discussion**

13 RNA viral infections are known to cause various skin eruptions, including characteristic
14 exanthems, maculopapular rashes, papulovesicular eruptions, and urticaria.¹³ Particularly
15 noteworthy is the occurrence of skin symptoms associated with the vascular system, such as
16 petechiae and purpura. A proposed hypothesis suggests these viruses trigger systemic
17 inflammation, complement activation, and microvascular injury, subsequently leading to
18 secondary vascular-related cutaneous symptoms.¹⁴

19 SARS-CoV-2's implication in vascular skin pathology offers valuable insight into the
20 mechanism for other RNA virus-attributed disruptions in vascular homeostasis (Figure 2).^{5,8}
21 Angiotensin-converting enzyme (ACE-2), the functional receptor utilized by SARS-CoV-2, is
22 abundantly expressed on endothelial cells, arterial smooth muscle cells, and microcirculation
23 pericytes, all components of the vascular microcirculation present in all organs, including the

1 skin. The binding of SARS-CoV-2 to ACE-2 upregulates levels of angiotensinogen II (AngII), a
2 strong vasoconstrictor and potent pro-inflammatory molecule known to generate excess free
3 radicals leading to a cascade of oxidative stress, endothelial cell damage, and thrombosis.^{15,16}
4 This explains SARS-CoV-2's ability to interrupt blood supply, injure vascular walls, and ulcerate
5 blood vessels.⁹ This severe cytokine storm may also contribute to the high rates of VTE, DVT,
6 PE, and other thrombotic complications observed.¹⁷ Likewise, vascular invasion by other RNA
7 viruses have been known to induce thrombotic ischemia and vascular occlusions.¹⁸ Here we
8 compare the prevalence of cutaneous manifestations associated with viral infections from each
9 family of RNA viruses.

10 *Coronaviridae - SARS-CoV-2 (COVID-19)*

11 Coronaviridae consists of a linear, positive-stranded RNA virus encased in a helical envelope.¹⁹
12 Reports indicate that dermatologic manifestations linked to COVID-19 infection have been
13 identified in as many as 20% of patients, with 44% showing symptoms at the onset of the
14 disease.^{5,6} Among the spectrum of cutaneous manifestations that emerged during the COVID-19
15 pandemic, the most frequently reported lesions include pseudo chilblains,
16 maculopapular/morbilliform eruptions, urticarial lesions, papulovesicular eruptions, and livedo-
17 like lesions. While evidence regarding COVID-19's predominant skin manifestations has varied,
18 recent studies indicate an increasing prevalence of maculopapular/erythematous rashes, with
19 pseudo-chilblains as the second most common presentation.²⁰⁻²⁴

20 Other cutaneous markers less commonly reported include acrodynia, dyshidrotic-like lesions,
21 periorbital erythema, eyelid dermatitis, skin rash resembling drug-related intertriginous and
22 flexural exanthema, erythema nodosum-like lesions, cutaneous hyperesthesia, dermatomyositis,
23 erythema nodosum-like Sweet's syndrome, pityriasis rosea (PR) and pityriasis rosea like

1 eruptions (PR-LE) and follicular eruptions.²² These non-specific skin symptoms may indicate a
2 potential SARS-CoV-2 infection, leading a provider to consider a diagnosis of COVID-19.

3 When cutaneous symptoms arise, and COVID-19 is suspected, providers may consider
4 conducting virological studies due to the potential for concurrent viral reactivation.^{25,26}
5 COVID-19, as well as COVID-19 vaccinations, have been associated with the reactivation of
6 other viruses. Implicated viruses include human herpes virus 6 and 7 (HHV-6/7), varicella-zoster
7 virus (VZV), Epstein-Barr virus (EBV), and herpes zoster (HZ). Research has suggested genetic
8 crosstalk between COVID-19 and herpes viruses, driven by elevated cytokine signaling
9 involving TH17 and interleukin-17 (IL-17).^{25,26} Both cytokines are elevated in COVID-19 and
10 herpes infections, and when concurrent, act synergistically, leading to excessive TH17
11 differentiation and a subsequent increase in circulating IL-17A. IL-17A can hinder viral
12 clearance by increasing pro-inflammatory and anti-apoptotic cytokines, impairing the destruction
13 of virus-infected cells.^{25,26}

14 This interaction may explain the risk of herpes virus reactivation in the presence of COVID-19
15 infections, indirectly contributing to the activation of PR.^{25,26} To differentiate between PR and
16 PR-LE, which mimics a drug eruption but is unrelated to HHV-6/7 infections, virological studies
17 are necessary. Considering the role of cytokines, particularly IL-17, future therapeutic
18 approaches may explore the modulation of IL-17 signaling as a possible treatment strategy.^{25,26}

19 Our findings of pseudo chilblains as the most frequently reported skin manifestation may be
20 attributed to the classification of nonspecific or generalized rashes under the category of
21 “unspecified rashes”, which may have included a significant proportion of morbilliform,

1 maculopapular, or erythematous rashes. These results are consistent with recent retrospective
2 multicenter reviews and other published studies.^{21,23,27}

3 COVID toes are frequently observed in children and young adults, typically presenting with mild
4 systemic COVID symptoms or even remaining asymptomatic.^{5,28} These cases usually test
5 negative on COVID-19 PCR tests, possibly due to the low viral load.²⁹ This could account for
6 underreporting of true rates of pernio toes, as asymptomatic individuals who tested negative for
7 COVID-19 are less likely to report their lesions. Individuals infected with pseudo chilblain may
8 exhibit mild flu-like symptoms 1-2 weeks preceding the appearance of pernio toes.^{5,28,30,31} An
9 alternative hypothesis proposes that pernio toes may represent an effective immune response
10 against COVID-19, particularly in patients with mild clinical symptoms.³⁰

11 *Orthomyxoviridae*

12 Influenza falls under the Orthomyxoviridae, and are single stranded, enveloped RNA with a
13 segmented genome.³² Rashes in influenza are infrequently observed, with approximately 2% of
14 patients exhibiting a maculopapular rash, consistent with our findings.^{33,34} Our study revealed a
15 small percentage of cases exhibited vasculitic rashes, with the majority being petechial in nature.
16 These observations are consistent with documented petechial exanths in influenza patients,
17 particularly among febrile children.^{30,31,33,35} Petechial rashes are typically indicative of severe
18 viral infections, and often present as terminal symptoms, hypothesized to be enduring effects of
19 an inflammatory response to the virus.³¹

20 The occurrence of petechial rashes in COVID-19 is similarly infrequent, with a reported
21 prevalence of 3% among COVID-19 infections.^{5,36} These cases also tend to emerge after the

1 onset of severe infection and manifest during the resolution phase, particularly among middle-
2 aged adults.³¹

3 *Picornaviridae*

4 Picornaviridae are small, positive sensed, non-enveloped, single stranded RNA viruses.³⁷

5 Coxsackie and enterovirus are infamous for causing hand, foot, and mouth disease (HFMD).^{38,39}

6 HFMD typically presents with herpangina, marked by oral ulcers as vesicles with erythematous

7 halos that rupture into superficial ulcers with a grey-yellow base. While skin lesions are not

8 common, they may manifest as maculopapular and vesicular rashes on the hands, feet, buttocks,

9 legs, and arms.^{38,39} Reports of localized maculopapular exanthems with petechiae have also been

10 reported.⁴⁰ Atypical echovirus infections, like Echovirus 9, are marked by a maculopapular and

11 petechial eruption that starts on the face or neck and spreads cephalocaudally.³⁹ Additionally,

12 punched-out ulcers on the soft palate or tonsils and grayish-white dots resembling Koplik spots

13 can appear as a typical enanthem.³⁹

14 Two distinct types of vesicular rashes associated with SARS-CoV-2 have been previously

15 established: the first characterized by a localized, monomorphic rash primarily affecting the

16 trunk, and the second marked by widespread, polymorphic vesicular rashes, distinguishing it

17 from varicella like lesions.⁴¹ COVID vesicular rashes are hypothesized to stem from an

18 inflammatory reaction and cytokine storm triggered by ACE2 in the skin, or alternatively, a

19 direct cytopathic impact of SARS-CoV-2 on the endothelial cells of dermal vessels.^{2,41}

20 Coxsackie oral infections are caused by the binding of coxsackie to an adenovirus receptor, a

21 component of the tight junction between cells in intact epithelium, while enteroviruses enter cells

22 via receptor mediated endocytosis.⁴² Coronaviruses affect the oral mucosa by inducing an

1 inflammatory response, causing significant increases in tumor necrosis factor related apoptosis
2 and interferon gamma production.⁴³ Oral mucosa is especially susceptible to SARS-CoV-2, as
3 these epithelial cells and salivary glands express ACE2, the entry receptor protein for COVID-
4 19.⁴³ This interaction allows COVID-19 replication and subsequent destruction, possibly
5 triggering the oral lesions. Other hypotheses suggest these lesions result from opportunistic
6 infections, potentially linked to immune system alterations and systemic damage.⁴³

7 *Flaviviridae*

8 Flaviviridae are linear, positive sensed, enveloped, single stranded RNA viruses.⁴⁴ Although
9 several diseases comprise the Flavivirus family, Dengue is the only disease that contributed to
10 this study. Dengue is the most common arbovirus infection, and 50-82% of patients report a
11 generalized skin eruption, including macules, papules, morbilliform, and petechial rashes
12 coinciding with our findings.⁴⁵ Mucosal involvement in up to 30% of cases has been reported.⁴⁵
13 Dengue is characterized as a hemorrhagic fever, commonly presenting with bleeding symptoms
14 such as petechiae, purpura, and gingival bleeding. Dengue and COVID-19 share symptoms such
15 as fever, arthralgia, myalgias, and thrombocytopenia, making it difficult to differentiate. There
16 has been reports of COVID-19 mistakenly misdiagnosed as dengue.⁴⁶ Petechial/purpuric lesions
17 in COVID-19 infections have been described in approximately 3% of patients, consistent with
18 our findings.⁵ Petechiae/purpuric lesions occur later in the clinical presentation; possible causes
19 may include a pauci-inflammatory thrombogenic vasculopathy, secondary viral infection,
20 COVID-19 drugs side effects, severe infection, or thrombocytopenia.⁵

21

22

23

1 *Togaviridae*

2 Togaviridae are positive sense, enveloped, single stranded RNA viruses.^{44,47} Togaviridae family
3 encompass the diseases of Rubella, Chikungunya, Zika and eastern and western equine
4 encephalitis. Rubella presents with a classic exanthem of maculopapular rash, described as a
5 fine, non-confluent rash beginning at the head and extending to the extremities, excluding the
6 palms and soles.^{47,48} Petechiae on the soft palate, also called Forchheimer spots, are observed in
7 approximately 20% of the patients. Although rare, thrombocytopenic purpura is also a known
8 complication of rubella. Rubella induces an immune response via spread by receptor mediated
9 endocytosis.⁴⁷

10 Skin manifestations in Zika typically occur 24 to 48 hours after the onset of the general flu-like
11 symptoms.⁴⁵ Rashes are mainly maculopapular and start on the face but can also be arranged in a
12 linear net-shape or wheals, with widespread distribution of blanching erythema. Skin findings are
13 variable and affect the face, palms, and soles accompanied by intense itching and scratching.
14 Oral aphthous ulcerations are also common.^{45,48}

15 The clinical symptoms of Chikungunya virus consist of fever, polyarthralgia, generalized skin
16 rash, and joint edema.⁴⁵ Skin findings include maculopapular rashes in a third of patients, and
17 petechial rashes are found in up to 80% of patients.^{39,45} Facial melanosis with nose pigmentation,
18 acral edema, chilblain like toes, purpura accentuated in photo-exposed areas, vesicle-bullous
19 eruptions, and ulcers, as well as hyperpigmentation over the axilla, perioral, and genital areas
20 have also been reported.⁴⁹ The initial site of infection in the human body is the skin, where
21 keratinocytes, melanocytes, and dermal fibroblasts are known to harbor the virus, contributing to
22 the observed hyperpigmentation. This viral presence prompts a robust interferon and
23 proinflammatory response.⁴⁵

1 The exact cause of acral edema observed in Chikungunya is not yet fully understood and is
2 hypothesized to arise from involvement of the lymphatic system secondary to systemic
3 inflammation, where inflammatory mediators such as interleukin 6, along with
4 cryoglobulinemia, may contribute. Pedal edema has been observed to occur after the resolution
5 of systemic symptoms in both Chikungunya and COVID-19 infected patients. Currently, no link
6 has been established between these two conditions, or whether there is a pathological connection
7 between acral edema and pernio toes seen in Chikungunya and SARS-CoV-2 infections.⁵⁰
8

9 *Retroviridae*

10 Retroviridae are positive sense, enveloped, single stranded RNA viruses that utilize reverse
11 transcriptase for replication.^{51,52} There are two types: HIV, responsible for AIDS, and HTLV,
12 linked to adult T cell leukemia. HIV exhibits varied symptoms based on infection stage and
13 opportunistic infections, leading to diverse skin manifestations. HTLV commonly results in
14 xerosis and ichthyosis-related conditions. Vasculitic lesions are the sole shared skin finding in
15 both viruses.^{51,52}
16

17 *Paramyxoviridae*

18 Paramyxoviridae are negative sensed, linear, enveloped, single stranded RNA viruses.⁵³
19 Subtypes include Pneumovirinae that manifests respiratory syncytial virus (RSV),
20 Paramyxovirinae encompassing Morbillivirus (Measles and Rubeola), Respirovirus (para-
21 influenza), and Rubulavirus (mumps and para-influenza). Viral infections within this family,
22 measles in particular, exhibit an erythematous maculopapular/morbilliform rash as a
23 characteristic feature.^{48,53} In addition, petechial lesions may also occur on the soft palate.³⁹

1 Morbilliform rashes are characteristic indicators of viral infections and adverse drug
2 reactions.^{5,7,48} Among patients with COVID-19, maculopapular rashes are among the most
3 prevalent skin manifestations, accounting for 70% of cases. Similarly, urticaria has been
4 associated with a prevalence as high as 19%, with 92% of cases associated with pruritis.²
5 These rashes have been associated with severe COVID infections, making it challenging to
6 distinguish them from drug reactions, as individuals with severe illness are often on medication.
7 Additionally, there are reports of rash development in the absence of medication use. One
8 hypothesis is that the heightened immune response to the body's inflammation may lead to
9 increased medication sensitivity.^{5,7} Another possibility is the result of direct localization of the
10 virus on the skin.^{2,41}

12 *Bunyaviridae*

13 Bunyaviridae are negative sensed, spherical, enveloped, single stranded RNA viruses.⁵⁴
14 Members of this family encompass a spectrum of hemorrhagic fevers and tickborne illnesses,
15 including but not limited to the Crimean Congo virus, Hantavirus, La Crosse virus, and Rift
16 Valley fever virus. Consistent with other types of viral hemorrhagic fevers, expected patient
17 symptoms include those associated with bleeding manifestations: petechiae, purpura, and
18 ecchymosis. Crimean Congo virus often begins with a petechial rash as the presenting
19 symptom.⁵⁵ Morbilliform eruptions and facial rashes are also well-known skin findings of
20 Crimean Congo virus, consistent with our findings. This virus also induces a proinflammatory
21 response and cytokine storm that can lead to shock.^{54,55}

22 The absence of documented vascular cutaneous manifestations in various RNA virus families,
23 particularly the Rhabdoviridae family, which, like the Coronaviridae family, is transmitted via

1 respiratory droplets, highlights the distinct nature of each family of viruses. Moreover, observing
2 these manifestations solely in specific RNA family members, such as Dengue within the
3 Flaviviridae family, further underscores that each family has unique members with specific
4 characteristics, and there may be exceptions or variations within each family.

6 **Limitations**

7 Adherence to specific exclusion criteria may have resulted in omitting relevant articles.
8 Additionally, restricted accessibility to articles published over 20 years ago could have limited
9 the historical perspective on the topic. Moreover, the rapidly increasing number of publications
10 on COVID-19 during the study execution may have led to certain recent findings not being
11 included. Certain factors related to patient characteristics, vaccination, and health status were not
12 accounted for in the selected articles, which could have influenced the observed skin
13 manifestations and severity. Also, variables such as the impact of drug usage, the presence of
14 multiple concurrent illnesses, and the possibility of coinfection with multiple viruses may have
15 contributed to the reported skin findings. Lastly, cases that tested negative for COVID were
16 excluded, which could impact the comprehensiveness of our analysis.

18 **Conclusion**

19 Various skin manifestations were observed across a range of RNA viruses, both inflammatory
20 and vascular. In the context of COVID and RNA infections, similar skin symptoms were
21 observed, including perniois or edematous toes, maculopapular/morbilliform rashes, urticarial
22 rashes, vesicular rashes, and oral ulcers, each with distinct mechanisms of infection linked to the
23 inflammatory response. Importantly, no vascular cutaneous pathology was linked to the

1 Reoviridae, Hepeviridae, Hepadnaviridae, Rhabdoviridae, Noroviridae, Filoviridae, and
2 Arenaviridae families. This review highlights the need for further exploration into the underlying
3 mechanisms driving cutaneous manifestations found in SARS-CoV-2 infected patients and
4 related RNA viruses.

6 References

71. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol.* 2020;34(5):e212-e213. doi:10.1111/JDV.16387
92. Martora F, Villani A, Fabbrocini G, Battista T. COVID-19 and cutaneous manifestations: A review of the published literature. *J Cosmet Dermatol.* 2023;22(1):4. doi:10.1111/JOCD.15477
123. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *Journal of the European Academy of Dermatology and Venereology.* 2020;34(5):e212-e213. doi:10.1111/JDV.16387
154. Brandão MGSA, Barros LM, de Aquino Mendonça J, de Oliveira AR, de Araújo TM, Veras VS. Clinical and histopathological findings of cutaneous manifestations of COVID-19 patients. *Dermatol Ther.* 2020;33(6). doi:10.1111/DTH.13926
185. Martora F, Villani A, Fabbrocini G, Battista T. COVID-19 and cutaneous manifestations: A review of the published literature. *J Cosmet Dermatol.* 2023;22(1):4. doi:10.1111/JOCD.15477
216. Tsai PH, Lai WY, Lin YY, et al. Clinical manifestation and disease progression in COVID-19 infection. *J Chin Med Assoc.* 2021;84(1):3-8. doi:10.1097/JCMA.0000000000000463
237. Danarti R, Limantara NV, Rini DLU, Budiarto A, Febriana SA, Soebono H. Cutaneous Manifestation in COVID-19: A Lesson Over 2 Years Into the Pandemic. *Clin Med Res.* 2023;21(1):36-45. doi:10.3121/CMR.2023.1598
268. Masood W, Ahmad S, Khan NA, et al. Pathobiology of Cutaneous Manifestations Associated with COVID-19 and Their Management. *Viruses.* 2022;14(9). doi:10.3390/V14091972
289. Acharya Y, Alameer A, Calpin · Gavin, Alkhatab M, Sherif Sultan ·. A comprehensive review of vascular complications in COVID-19. *J Thromb Thrombolysis.* 1234;53:586-593. doi:10.1007/s11239-021-02593-2
3110. Rocha KO, Zanuncio VV, Freitas BAC de, Lima LM. “COVID toes”: A meta-analysis of case and observational studies on clinical, histopathological, and laboratory findings. *Pediatr Dermatol.* 2021;38(5):1143-1149. doi:10.1111/pde.14805
3411. Wong JSC, Wong TS, Chua GT, et al. COVID toe in an adolescent boy: a case report. *Hong Kong Med J.* 2022;28(2):175-177. doi:10.12809/HKMJ219690
3612. Okorie CL, Salem I, Davis MJ, Mann JA. A case of late ulceration of infantile hemangioma in the setting of SARS-CoV2 infection. *JAAD Case Rep.* 2023;31:109-111. doi:10.1016/J.JDCR.2022.10.037
3913. Anci E, Braun C, Marinosci A, et al. Viral Infections and Cutaneous Drug-Related Eruptions. *Front Pharmacol.* 2020;11. doi:10.3389/FPHAR.2020.586407

114. Marzano AV, Genovese G, Moltrasio C, et al. The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. *J Am Acad Dermatol.* 2021;84(5):1356. doi:10.1016/J.JAAD.2021.01.023
415. Beacon TH, Delcuve GP, Davie JR. Epigenetic regulation of ACE2, the receptor of the SARS-CoV-2 virus. *Genome.* 2021;64(4):386-399. doi:10.1139/GEN-2020-0124/ASSET/IMAGES/LARGE/GEN-2020-0124F5.JPEG
716. Jarrott B, Head R, Pringle KG, Lumbers ER, Martin JH. “LONG COVID”—A hypothesis for understanding the biological basis and pharmacological treatment strategy. *Pharmacol Res Perspect.* 2022;10(1):e00911. doi:10.1002/PRP2.911
1017. Marzano AV, Genovese G, Moltrasio C, et al. The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. *J Am Acad Dermatol.* 2021;84(5):1356. doi:10.1016/J.JAAD.2021.01.023
1318. Elmas ÖF, Demirbaş A, Özyurt K, Atasoy M, Türsen Ü. Cutaneous manifestations of COVID-19: A review of the published literature. *Dermatol Ther.* 2020;33(4). doi:10.1111/DTH.13696
1619. Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *Int J Surg.* 2020;76:71-76. doi:10.1016/J.IJSU.2020.02.034
1920. Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. *J Am Acad Dermatol.* 2020;83(4):1118-1129. doi:10.1016/J.JAAD.2020.06.1016
2221. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol.* 2020;183(1):71. doi:10.1111/BJD.19163
2522. Danarti R, Limantara NV, Rini DLU, Budiarto A, Febriana SA, Soebono H. Cutaneous Manifestation in COVID-19: A Lesson Over 2 Years Into the Pandemic. *Clin Med Res.* 2023;21(1):36-45. doi:10.3121/CMR.2023.1598
2823. Jia JL, Kamceva M, Rao SA, Linos E. Cutaneous manifestations of COVID-19: A preliminary review. *J Am Acad Dermatol.* 2020;83(2):687-690. doi:10.1016/j.jaad.2020.05.059
3124. Bassetti M, Massone C, Vena A, et al. Skin manifestations in patients with coronavirus disease 2019. *Curr Opin Infect Dis.* 2022;35(2):88. doi:10.1097/QCO.0000000000000816
3325. Drago F, Broccolo F, Ciccarese G. Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination. *Clin Dermatol.* 2022;40(5):586. doi:10.1016/J.CLINDERMATOL.2022.01.002
3626. Yu X, Li L, Chan MTV, Wu WKK. Bioinformatic analyses suggest augmented interleukin-17 signaling as the mechanism of COVID-19-associated herpes zoster. *Environ Sci Pollut Res Int.* 2021;28(46):65769. doi:10.1007/S11356-021-15567-X
3927. Cestari S da CP, Cestari M da CP, Marques GF, Lirio I, Tovo R, Cruz Silva Labriola I. Cutaneous manifestations of COVID-19 patients in a Hospital in São Paulo, Brazil, and global literature review. *An Bras Dermatol.* 2023;98(4):466. doi:10.1016/J.ABD.2022.09.007
4228. Neale H, Hawryluk EB. COVID-19 Pediatric Dermatology. *Dermatol Clin.* 2021;39(4):505. doi:10.1016/J.DET.2021.05.012
4429. Koschitzky M, Oyola RR, Lee-Wong M, Abittan B, Silverberg N. Pediatric COVID toes and fingers. *Clin Dermatol.* 2021;39(1):84-91. doi:10.1016/J.CLINDERMATOL.2020.12.016

130. Koschitzky M, Oyola RR, Lee-Wong M, Abittan B, Silverberg N. Pediatric COVID toes and fingers. *Clin Dermatol*. 2021;39(1):84-91. doi:10.1016/J.CLINDERMATOL.2020.12.016
331. Kang JH. Febrile Illness with Skin Rashes. *Infect Chemother*. 2015;47(3):155. doi:10.3947/IC.2015.47.3.155
532. Rao S, Nyquist AC, Stillwell PC. Influenza. *Kendig's Disorders of the Respiratory Tract in Children*. Published online January 1, 2019:460-465.e2. doi:10.1016/B978-0-323-44887-1.00027-4
833. Fretzayas A, Moustaki M, Kotzia D, Nicolaidou P. Rash, an uncommon but existing feature of H1N1 influenza among children. *Influenza Other Respir Viruses*. 2011;5(4):223. doi:10.1111/J.1750-2659.2011.00197.X
1134. Lee HJ, Shin DH, Choi JS, Kim KH. Leukocytoclastic Vasculitis Associated with Influenza A Virus Infection. *J Korean Med Sci*. 2012;27(12):1601. doi:10.3346/JKMS.2012.27.12.1601
1335. Skowronski DM, Chambers C, Osei W, et al. Case series of rash associated with influenza B in school children. *Influenza Other Respir Viruses*. 2015;9(1):32. doi:10.1111/IRV.12296
1536. Kang JH. Febrile Illness with Skin Rashes. *Infect Chemother*. 2015;47(3):155. doi:10.3947/IC.2015.47.3.155
1737. Tuthill TJ, GropPELLI E, Hogle JM, Rowlands DJ. Picornaviruses. *Curr Top Microbiol Immunol*. 2010;343:43. doi:10.1007/82_2010_37
1938. Guerra AM, Orille E, Waseem M. Hand, Foot, and Mouth Disease. *StatPearls*. Published online October 9, 2022. Accessed August 11, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK431082/>
2239. Drago F, Ciccarese G, Merlo G, et al. Oral and cutaneous manifestations of viral and bacterial infections: Not only COVID-19 disease. *Clin Dermatol*. 2021;39(3):384. doi:10.1016/J.CLINDERMATOL.2021.01.021
2540. Drago F, Ciccarese G, Gariazzo L, Cioni M, Parodi A. Acute localized exanthem due to Coxsackievirus A4. *Infez Med*. 2017;25(3):274-276. Accessed October 19, 2023. <https://pubmed.ncbi.nlm.nih.gov/28956547/>
2841. Masood W, Ahmad S, Khan NA, et al. Pathobiology of Cutaneous Manifestations Associated with COVID-19 and Their Management. *Viruses*. 2022;14(9). doi:10.3390/V14091972
3042. Tariq N, Kyriakopoulos C. Group B Coxsackie Virus. *StatPearls*. Published online July 10, 2023. Accessed October 20, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK560783/>
3243. Gutierrez-Camacho JR, Avila-Carrasco L, Martinez-Vazquez MC, et al. Oral Lesions Associated with COVID-19 and the Participation of the Buccal Cavity as a Key Player for Establishment of Immunity against SARS-CoV-2. *Int J Environ Res Public Health*. 2022;19(18). doi:10.3390/IJERPH191811383
3644. Zhang X, Jia R, Shen H, Wang M, Yin Z, Cheng A. Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections. *Viruses*. 2017;9(11). doi:10.3390/V9110338
3845. Atzori L, Ferrel C, Mateeva V, Vassileva S, Rongioletti F. Clinicopathologic features among different viral epidemic outbreaks involving the skin. *Clin Dermatol*. 2022;40(5):573. doi:10.1016/J.CLINDERMATOL.2021.06.003
4146. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. *J Am Acad Dermatol*. 2020;82(5):e177. doi:10.1016/J.JAAD.2020.03.036
4347. Leonor MC, Mendez MD. Rubella. *Infections in Pregnancy: An Evidence-Based Approach*. Published online January 31, 2023:63-66. doi:10.1017/9781108650434.010

148. Sharma S, Raby E, Prasad Kumarasinghe S. Cutaneous manifestations and dermatological sequelae of Covid-19 infection compared to those from other viruses. *Australas J Dermatol.* 2021;62(2):141. doi:10.1111/AJD.13561
449. De Oliveira Sá MVB, Carvalho DSAL, Vasconcelos LRS. Chilblains Associated with Chronic Chikungunya. *Am J Trop Med Hyg.* 2022;106(2):380. doi:10.4269/AJTMH.21-0884
650. Pustake M, Ganiyani MA, Shah D, Dhondge V, Deshmukh K. Post Chikungunya Fever and Post COVID-19 Bilateral Pedal Edema: A Case Report. *Cureus.* 2022;14(8). doi:10.7759/CUREUS.27588
951. Pitchumoni CS, Brun A. HIV Disease Current Practice. *Geriatric Gastroenterology.* Published online September 20, 2022:659-666. doi:10.1007/978-1-4419-1623-5_71
1152. Bryan ES, Tadi P. Human T-Cell Lymphotropic Virus. *Principles and Practice of Pediatric Infectious Diseases: Fourth Edition.* Published online July 4, 2022:1165-1165.e1. doi:10.1016/B978-1-4377-2702-9.00234-8
1453. Paramyxovirus - PubMed. Accessed August 13, 2023. <https://pubmed.ncbi.nlm.nih.gov/33620863/>
54. Shayan S, Bokaeian M, Shahrivar MR, Chinikar S. Crimean-Congo Hemorrhagic Fever. *Lab Med.* 2015;46(3):180-189. doi:10.1309/LMN1P2FRZ7BKZSCO
55. Duygu F, Sari T, Gunal O, Barut S, Atay A, Aytekin F. Cutaneous Findings of Crimean-Congo Hemorrhagic Fever: a Study of 269 Cases. *Jpn J Infect Dis.* 2018;71(6):408-412. doi:10.7883/YOKEN.JJID.2018.005
56. Ghafoor R, Ali SM, Goldust M. Cutaneous manifestations of Coronavirus Disease 2019. *J Cosmet Dermatol.* 2022;21(9):3667-3672. doi:10.1111/JOCD.15258
57. Waqas B, Salgado F, Harp J. Retiform Purpura on the Buttocks in 6 Critically Ill COVID-19 Patients. *Cutis.* 2021;108(5):E13-E14. doi:10.12788/CUTIS.0397
58. El Hasbani G, Taher AT, Jawad ASM, Uthman I. Henoch-Schönlein purpura: Another COVID-19 complication. *Pediatr Dermatol.* 2021;38(5):1359-1360. doi:10.1111/PDE.14699
59. Fujimoto LBM, Ferreira S de AD, Santos FB dos, Talhari C. Petechial lesions in a patient with COVID-19. *An Bras Dermatol.* 2021;96(1):111. doi:10.1016/J.ABD.2020.08.007
60. Schenker HM, Hagen M, Simon D, Schett G, Manger B. Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection. *Rheumatology (Oxford).* 2021;60(1):479-480. doi:10.1093/RHEUMATOLOGY/KEAA689
61. Silva DHM, Oppenheimer AR, Cunha T do AC. Purpuric rash on the legs of a patient with coronavirus disease. *Rev Soc Bras Med Trop.* 2020;53:e20200464. doi:10.1590/0037-8682-0464-2020
62. Levraut M, Ottavi M, Lechtman S, Mondain V, Jeandel PY. Immune thrombocytopenic purpura after COVID-19 infection. *Int J Lab Hematol.* 2021;43(1):e28. doi:10.1111/IJLH.13346
63. Ciccacese G, Drago F, Boatti M, Porro A, Muzic SI, Parodi A. Oral erosions and petechiae during SARS-CoV-2 infection. *J Med Virol.* 2021;93(1):129-132. doi:10.1002/JMV.26221
64. Karaca Z, Yayli S, Çalışkan O. A unilateral purpuric rash in a patient with COVID-19 infection. *Dermatol Ther.* 2020;33(4). doi:10.1111/DTH.13798
65. Wollina U. Schamberg-like purpuric eruptions and tonsillitis in mild COVID-19. *Dermatol Ther.* 2020;33(4). doi:10.1111/DTH.13766
66. Zulfikar AA, Lorenzo-Villalba N, Hassler P, Andrés E. Immune Thrombocytopenic Purpura in a Patient with Covid-19. *New England Journal of Medicine.* 2020;382(18):e43. doi:10.1056/NEJMC2010472/SUPPL_FILE/NEJMC2010472_DISCLOSURES.PDF

- 1 67. Méndez Maestro I, Peña Merino L, Udondo González del Tánago B, et al. Skin
2 manifestations in patients hospitalized with confirmed COVID-19 disease: a cross-sectional
3 study in a tertiary hospital. *Int J Dermatol*. 2020;59(11):1353. doi:10.1111/IJD.15180
- 4 68. Fulgencio-Barbarin J, Calleja-Algarra A, Morales-Raya C. COVID-19 induced systemic
5 thrombosis. *Med Clin (Engl Ed)*. 2020;155(6):278. doi:10.1016/J.MEDCLE.2020.05.018
- 6 69. Ghimire K, Adhikari N. Morbilliform Rashes in a Patient with COVID-19 Infection: A Case
7 Report. *JNMA J Nepal Med Assoc*. 2021;59(236):399. doi:10.31729/JNMA.5128
- 8 70. Morales MH, Leigh CL, Simon EL. COVID-19 infection with extensive thrombosis: A case
9 of phlegmasia cerulea dolens. *Am J Emerg Med*. 2020;38(9):1978.e1.
10 doi:10.1016/J.AJEM.2020.05.022
- 11 71. Berrebi D, Farmer W, Zinn Z. BASCULE syndrome in a child with prior asymptomatic
12 COVID-19 infection. *Pediatr Dermatol*. 2021;38(5):1342-1344. doi:10.1111/PDE.14821
- 13 72. Calton R, Paul P, Calton N. COVID-19 acral lesions showing pauciinflammatory thrombotic
14 microvasculopathy. *Indian J Pathol Microbiol*. 2021;64(3):600.
15 doi:10.4103/IJPM.IJPM_884_20
- 16 73. Phamduy TT, Young DM, Ramolia PB. Localized Scarletiform Rash of the Ears and
17 Antecubital Fossa in COVID-19. *The Journal of the American Board of Family
18 Medicine*. 2021;34(Supplement):S183-S185. doi:10.3122/JABFM.2021.S1.200152
- 19 74. Capoferri G, Daikeler T, Mühleisen B, Trendelenburg M, Müller S. Cutaneous
20 leukocytoclastic vasculitis secondary to COVID-19 infection leading to extensive skin
21 necrosis. *Clin Dermatol*. 2022;40(4):397. doi:10.1016/J.CLINDERMATOL.2022.02.013
- 22 75. Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: Report of
23 three cases and a review of literature. *J Dermatol Sci*. 2020;98(2):75-81.
24 doi:10.1016/J.JDERMSCI.2020.04.011
- 25 76. Gaspar AD, de Sio Puetter Kuzma G, Amancio L, et al. Multisystem inflammatory
26 syndrome in children: a case series. *Rev Paul Pediatr*. 2022;40. doi:10.1590/1984-
27 0462/2022/40/2021046
- 28 77. Novara E, Molinaro E, Benedetti I, Bonometti R, Lauritano EC, Boverio R. Severe acute
29 dried gangrene in COVID-19 infection: a case report. *Eur Rev Med Pharmacol Sci*.
30 2020;24(10):5769-5771. doi:10.26355/EURREV_202005_21369
- 31 78. Demissie M, Deribessa SJ, Bacha T. A Typical Case of Multisystem Inflammatory
32 Syndrome in a 10-yearold Girl with COVID-19: A Case Report from Ethiopia. *Ethiop J
33 Health Sci*. 2022;32(4):873-877. doi:10.4314/EJHS.V32I4.26
- 34 79. Paparella R, Tarani L, Properzi E, et al. Chilblain-like lesions onset during SARS-CoV-2
35 infection in a COVID-19-vaccinated adolescent: case report and review of literature. *Ital J
36 Pediatr*. 2022;48(1). doi:10.1186/S13052-022-01296-5
- 37 80. Colonna C, Monzani NA, Rocchi A, Gianotti R, Boggio F, Gelmetti C. Chilblain-like lesions
38 in children following suspected COVID-19 infection. *Pediatr Dermatol*. 2020;37(3):437.
39 doi:10.1111/PDE.14210
- 40 81. Mascitti H, Jourdain P, Bleibtreu A, et al. Prognosis of rash and chilblain-like lesions among
41 outpatients with COVID-19: a large cohort study. *Eur J Clin Microbiol Infect Dis*.
42 2021;40(10):2243-2248. doi:10.1007/S10096-021-04305-3
- 43 82. Gooch MD. A New Rash Differential: CoVID-19. *Adv Emerg Nurs J*. 2021;43(1):28-34.
44 doi:10.1097/TME.0000000000000336

- 1 83. Ocampo-Candiani J, Ramos-Cavazos CJ, Arellano-Mendoza MI, et al. International registry
2 of dermatological manifestations secondary to COVID-19 infection in 347 Hispanic patients
3 from 25 countries. *Int J Dermatol*. 2021;60(8):956-963. doi:10.1111/IJD.15632
- 4 84. Brancaccio G, Gussetti N, Sasset L, et al. Cutaneous manifestations in a series of 417
5 patients with SARS-CoV-2 infection: epidemiological and clinical correlates of chilblain like
6 lesions. *Pathog Glob Health*. 2021;115(7-8):483. doi:10.1080/20477724.2021.1901040
- 7 85. Larenas-Linnemann D, Luna-Pech J, Navarrete-Rodríguez EM, et al. Cutaneous
8 Manifestations Related to COVID-19 Immune Dysregulation in the Pediatric Age Group.
9 *Curr Allergy Asthma Rep*. 2021;21(2). doi:10.1007/S11882-020-00986-6
- 10 86. Vázquez-Osorio I, Rocamonde L, Treviño-Castellano M, Vázquez-Veiga H, Ginarte M.
11 Pseudo-chilblain lesions and COVID-19: a controversial relationship. *Int J Dermatol*.
12 2021;60(6):754-756. doi:10.1111/IJD.15422
- 13 87. Jacquin-Porretaz C, Ducourneau A, Dupond AS, Nardin C, Aubin F, Courtieu C. Cutaneous
14 manifestations of COVID-19 in the Franche-Comté region of France: A monocentric study.
15 *Ann Dermatol Venereol*. 2021;148(2):124. doi:10.1016/J.ANNDER.2020.12.002
- 16 88. Widysanto A, Wahyuni TD, Simanjuntak LH, et al. Ecchymosis in critical coronavirus
17 disease 2019 (COVID-19) patient in Tangerang, Indonesia: a case report. *J Thromb*
18 *Thrombolysis*. 2021;52(2):635-639. doi:10.1007/S11239-020-02338-7
- 19 89. Rubin A, Alamgir M, Rubin J, Rao BK. Chilblain-like lesions with prominent bullae in a
20 patient with COVID-19. *BMJ Case Reports CP*. 2020;13(11):e237917. doi:10.1136/BCR-
21 2020-237917
- 22 90. Andina D, Colmenero I, Santonja C, et al. Suspected COVID-19-related reticulated purpura
23 of the soles in an infant. *Pediatr Dermatol*. 2021;38(1):301-303. doi:10.1111/PDE.14409
- 24 91. Fertitta L, Welfringer-Morin A, Ouedrani A, et al. Immunological and virological profile of
25 children with chilblain-like lesions and SARS-CoV-2. *J Eur Acad Dermatol Venereol*.
26 2021;35(3):e164-e167. doi:10.1111/JDV.16972
- 27 92. Gambichler T, Reuther J, Stücker M, et al. SARS-CoV-2 spike protein is present in both
28 endothelial and eccrine cells of a chilblain-like skin lesion. *J Eur Acad Dermatol Venereol*.
29 2021;35(3):e187-e189. doi:10.1111/JDV.16970
- 30 93. Andina D, Noguera-Morel L, Bascuas-Arribas M, et al. Chilblains in children in the setting
31 of COVID-19 pandemic. *Pediatr Dermatol*. 2020;37(3):406. doi:10.1111/PDE.14215
- 32 94. Garcia-Lara G, Linares-González L, Ródenas-Herranz T, Ruiz-Villaverde R. Chilblain-like
33 lesions in pediatrics dermatological outpatients during the COVID-19 outbreak. *Dermatol*
34 *Ther*. 2020;33(5). doi:10.1111/DTH.13516
- 35 95. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and
36 hands during the COVID-19 Pandemic. *Int J Dermatol*. 2020;59(6):739.
37 doi:10.1111/IJD.14937
- 38 96. Chen ZH, Qin XC, Song R, et al. Co-circulation of multiple hemorrhagic fever diseases with
39 distinct clinical characteristics in Dandong, China. *PLoS One*. 2014;9(2).
40 doi:10.1371/JOURNAL.PONE.0089896
- 41 97. Çevik MA, Erbay A, Bodur H, et al. Clinical and laboratory features of Crimean-Congo
42 hemorrhagic fever: predictors of fatality. *Int J Infect Dis*. 2008;12(4):374-379.
43 doi:10.1016/J.IJID.2007.09.010
- 44 98. Kaya S, Elaldi N, Kubar A, et al. Sequential determination of serum viral titers, virus-
45 specific IgG antibodies, and TNF- α , IL-6, IL-10, and IFN- γ levels in patients with Crimean-
46 Congo hemorrhagic fever. *BMC Infect Dis*. 2014;14(1). doi:10.1186/1471-2334-14-416

- 1 99. Ozkurt Z, Kiki I, Erol S, et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical
2 features, risk factors and efficacy of ribavirin therapy. *J Infect.* 2006;52(3):207-215.
3 doi:10.1016/J.JINF.2005.05.003
- 4 100. Karli A, Sensoy G, Albayrak C, et al. Pancytopenia As the Initial Manifestation of
5 Brucellosis in Children. *Vector Borne Zoonotic Dis.* 2015;15(9):545-549.
6 doi:10.1089/VBZ.2015.1775
- 7 101. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical
8 pathology of Crimean-Congo hemorrhagic fever. *Rev Infect Dis.* 1989;11 Suppl 4:794-800.
9 doi:10.1093/CLINIDS/11.SUPPLEMENT_4.S794
- 10 102. Wang G, Chang H, Jia B, et al. Nucleocapsid protein-specific IgM antibody responses in the
11 disease progression of severe fever with thrombocytopenia syndrome. *Ticks Tick Borne Dis.*
12 2019;10(3):639-646. doi:10.1016/J.TTBDIS.2019.02.003
- 13 103. Chen CH, Huang YC, Kuo KC, Li CC. Clinical features and dynamic ordinary laboratory
14 tests differentiating dengue fever from other febrile illnesses in children. *J Microbiol*
15 *Immunol Infect.* 2018;51(5):614-620. doi:10.1016/J.JMII.2016.08.018
- 16 104. Capeding RZ, Brion JD, Caponpon MM, et al. The Incidence, Characteristics, and
17 Presentation of Dengue Virus Infections during Infancy. *Am J Trop Med Hyg.*
18 2010;82(2):330. doi:10.4269/AJTMH.2010.09-0542
- 19 105. Richards AL, Bagus R, Baso SM, et al. The first reported outbreak of dengue hemorrhagic
20 fever in Irian Jaya, Indonesia. *Am J Trop Med Hyg.* 1997;57(1):49-55.
21 doi:10.4269/AJTMH.1997.57.49
- 22 106. Fernández E, Smieja M, Walter SD, Loeb M. A predictive model to differentiate dengue
23 from other febrile illness. *BMC Infect Dis.* 2016;16(1). doi:10.1186/S12879-016-2024-Y
- 24 107. Ageep AK, Malik AA, Elkarsani MS. Clinical presentations and laboratory findings in
25 suspected cases of dengue virus. *Saudi Med J.* 2006;27(11):1711-1713.
- 26 108. Thomas EA, John M, Bhatia A. Cutaneous manifestations of dengue viral infection in Punjab
27 (north India). *Int J Dermatol.* 2007;46(7):715-719. doi:10.1111/J.1365-4632.2007.03298.X
- 28 109. Senaratne T, Wimalaratne H, Alahakoon DGS, Gunawardane N, Carr J, Noordeen F.
29 Characterization of dengue virus infections in a sample of patients suggests unique clinical,
30 immunological, and virological profiles that impact on the diagnosis of dengue and dengue
31 hemorrhagic fever *J Med Virol.* 2016;88(10):1703-1710. doi:10.1002/JMV.24525
- 32 110. Hayes C, O'Rourke T, Fogelman V, Leavengood D, Crow G, Albersmeyer M. Dengue fever
33 in American military personnel in the Philippines: clinical observations on hospitalized
34 patients during a 1984 epidemic. *Southeast Asian J Trop Med Public Health.* 1989;20(1):1-
35 8.
- 36 111. Biswas HH, Ortega O, Gordon A, et al. Early clinical features of dengue virus infection in
37 nicaraguan children: a longitudinal analysis. *PLoS Negl Trop Dis.* 2012;6(3).
38 doi:10.1371/JOURNAL.PNTD.0001562
- 39 112. Hō TS, Wang SM, Lin YS, Liu CC. Clinical and laboratory predictive markers for acute
40 dengue infection. *J Biomed Sci.* 2013;20(1). doi:10.1186/1423-0127-20-75
- 41 113. Sahana KS, Sujatha R. Clinical profile of dengue among children according to revised WHO
42 classification: analysis of a 2012 outbreak from Southern India. *Indian J Pediatr.*
43 2015;82(2):109-113. doi:10.1007/S12098-014-1523-3
- 44 114. Kaneko H, Ohkawara Y, Nomura K, Horiike S, Taniwaki M. Relapse of idiopathic
45 thrombocytopenic purpura caused by influenza A virus infection: a case report. *J Infect*
46 *Chemother.* 2004;10(6):364-366. doi:10.1007/S10156-004-0343-1

- 1 115. Shachor-Meyouhas Y, Kassis I. Petechial rash with pandemic influenza (H1N1) infection.
2 *Pediatr Infect Dis J.* 2010;29(5):480. doi:10.1097/INF.0B013E3181D40CED
- 3 116. Lee CY, Wu MC, Chen PY, Chou TY, Chan YJ. Acute immune thrombocytopenic purpura
4 in an adolescent with 2009 novel H1N1 influenza A virus infection. *Journal of the Chinese*
5 *Medical Association.* 2011;74(9):425-427. doi:10.1016/J.JCMA.2011.08.010
- 6 117. Arakawa Y, Matsui A, Sasaki N, Nakayama T. Agranulocytosis and thrombocytopenic
7 purpura following measles infection in a living-related orthotopic liver transplantation
8 recipient. *Acta Paediatr Jpn.* 1997;39(2):226-229. doi:10.1111/J.1442-
9 200X.1997.TB03587.X
- 10 118. Oncel I, Saltik S, Anlar B. Subacute sclerosing panencephalitis and immune
11 thrombocytopenia: More than a coincidence? *Med Hypotheses.* 2018;111:70-72.
12 doi:10.1016/J.MEHY.2017.12.028
- 13 119. Pérez-Ferriols A, Martínez-Aparicio A, Aliaga-Boniche A. Papular-purpuric “gloves and
14 socks” syndrome caused by measles virus. *J Am Acad Dermatol.* 1994;30(2 Pt 1):291-292.
15 doi:10.1016/S0190-9622(08)81938-X
- 16 120. Coffin SE, Gest KL, Shimamura A. Respiratory syncytial virus as a cause of fever and
17 petechiae in infants. *Clin Pediatr (Phila).* 1993;32(6):355-356.
18 doi:10.1177/000992289303200606
- 19 121. Orteu CH, McGregor JM, Whittaker SJ, Balzola F, Wakefield AJ. Erythema elevatum
20 diutinum and Crohn disease: a common pathogenic role for measles virus? *Arch Dermatol.*
21 1996;132(12):1523-1525. doi:10.1001/ARCHDERM.132.12.1523
- 22 122. Lee CJ, Huang YC, Yang S, et al. Clinical Features of Coxsackievirus A4, B3 and B4
23 Infections in Children. *PLoS One.* 2014;9(2):e87391.
24 doi:10.1371/JOURNAL.PONE.0087391
- 25 123. Lee HY, Chen CJ, Huang YC, et al. Clinical features of echovirus 6 and 9 infections in
26 children. *Journal of Clinical Virology.* 2010;49(3):175-179. doi:10.1016/J.JCV.2010.07.010
- 27 124. Horsten HH, Kemp M, Fischer TK, Lindahl KH, Bygum A. Atypical Hand, Foot, and Mouth
28 Disease Caused by Coxsackievirus A6 in Denmark: A Diagnostic Mimicker. *Acta Derm*
29 *Venereol.* 2018;98(3):350-354. doi:10.2340/00015555-2853
- 30 125. Broccolo F, Drago F, Ciccarese G, et al. Severe atypical hand-foot-and-mouth disease in
31 adults due to coxsackievirus A6: Clinical presentation and phylogenesis of CV-A6 strains. *J*
32 *Clin Virol.* 2019;110:1-6. doi:10.1016/J.JCV.2018.11.003
- 33 126. Ibarra H, Zapata C, Inostroza J, Mezzano S, Riedemann S. Immune thrombocytopenic
34 purpura associated with hepatitis A. *Blut.* 1986;52(6):371-375. doi:10.1007/BF00320784
- 35 127. Anderson CW, Shah MBBS PA, Roberts JR. Adult-Onset Still’s Disease: Is This Truly a
36 Diagnosis of Exclusion? *Hawai’i Journal of Medicine & Public Health.* 2017;76(11 Suppl
37 2):3. Accessed August 15, 2023. /pmc/articles/PMC5696586/
- 38 128. Kobayashi KI, Haruta T, Kubota M, Akiyoshi K, Suga T, Ito M. Clinical spectrum in
39 hospitalized children with echovirus type 13 infection. *Pediatrics international* 2005;47:185-
40 9. - Google Search. Accessed August 15, 2023.
41 https://www.google.com/search?q=Kobayashi+KI%2C+Haruta+T%2C+Kubota+M%2C+Akiyoshi+K%2C+Suga+T%2C+Ito+M.+Clinical+spectrum+in+hospitalized+children+with+echovirus+type+13+infection.+Pediatrics+international+2005%3B47%3A185-9.&rlz=1C5CHFA_enUS860US861&oq=Kobayashi+KI%2C+Haruta+T%2C+Kubota+M%2C+Akiyoshi+K%2C+Suga+T%2C+Ito+M.+Clinical+spectrum+in+hospitalized+children+with+echovirus+type+13+infection.+Pediatrics+international+2005%3B47%3A185-
42
43
44
45
46

- 1 9.&gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg70gEHMjgwajBqNKgCALACA
2 A&sourceid=chrome&ie=UTF-8
- 3 129. Okada J, Imafuku S, Tsujita J, Moroi Y, Urabe K, Furue M. Case of adult T-cell
4 leukemia/lymphoma manifesting marked purpura. *J Dermatol.* 2007;34(11):782-785.
5 doi:10.1111/J.1346-8138.2007.00384.X
- 6 130. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis
7 C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe
8 d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de
9 l'Hepatitis C. *Medicine.* 2000;79(1):47-56. doi:10.1097/00005792-200001000-00005
- 10 131. Posada-Vergara MP, Montanheiro P, Fukumori LMI, et al. Clinical and epidemiological
11 aspects of HTLV-II infection in São Paulo, Brazil: presence of tropical spastic
12 paraparesis/HTLV-associated myelopathy (TSP/HAM) simile diagnosis in HIV-1-co-
13 infected subjects. *Rev Inst Med Trop Sao Paulo.* 2006;48(4):207-210. doi:10.1590/S0036-
14 46652006000400006
- 15 132. Brand M, Woodiwiss AJ, Michel F, Nayler S, Veller MG, Norton GR. Large Vessel
16 Adventitial Vasculitis Characterizes Patients with Critical Lower Limb Ischemia with as
17 Compared to without Human Immunodeficiency Virus Infection. *PLoS One.*
18 2014;9(8):e106205. doi:10.1371/JOURNAL.PONE.0106205
- 19 133. Sugimoto T, Tsuda A, Kito K, Uzu T, Kashiwagi A. Henoch-Schönlein purpura in a patient
20 with human immunodeficiency virus infection. *Rheumatol Int.* 2008;28(6):615-616.
21 doi:10.1007/S00296-007-0492-5/METRICS
- 22 134. Bani-Sadr F, Chakvetadze C, Galperine T, et al. Biphasic hepatitis A with severe cholestasis
23 and thrombocytopenic purpura in an HIV-1-infected male patient. *Med Mal Infect.*
24 2014;44(2):81-82. doi:10.1016/J.MEDMAL.2013.12.001
- 25 135. Bunupuradah T, Puthanakit T, Pancharoen C, Butterworth O, Phanuphak P, Ananworanich J.
26 Henoch-Schönlein purpura and thrombocytopenia after planned antiretroviral treatment
27 interruption in a Thai girl with HIV infection. *Int J Infect Dis.* 2009;13(1).
28 doi:10.1016/J.IJID.2008.05.1225
- 29 136. Persaud D, Chandwani S, Rigaud M, et al. Delayed recognition of human immunodeficiency
30 virus infection in preadolescent children. *Pediatrics.* 1992;90(5):688-691.
- 31 137. Zaid M, Tan K, Smitasin N, Tambyah PA, Archuleta S. Henoch-Schönlein purpura
32 associated with adult human immunodeficiency virus infection: case report and review of the
33 literature. *Ann Acad Med Singap.* 2013;42(7):358-360.
- 34 138. Sugishita Y, Shimatani N, Katow S, Takahashi T, Hori N. Epidemiological characteristics of
35 rubella and congenital rubella syndrome in the 2012-2013 epidemics in Tokyo, Japan. *Jpn J*
36 *Infect Dis.* 2015;68(2):159-165. doi:10.7883/YOKEN.JJID.2014.195
- 37 139. Kannan M, Rajendran R, Sunish IP, et al. A study on chikungunya outbreak during 2007 in
38 Kerala, south India. *Indian J Med Res.* Published online 2009.
- 39 140. Cooper LZ, Krugman S. Clinical manifestations of postnatal and congenital rubella. *Arch*
40 *Ophthalmol.* 1967;77(4):434-439. doi:10.1001/ARCHOPHT.1967.00980020436004
- 41 141. Ramacciotti E, Agati LB, Aguiar VCR, et al. Zika and Chikungunya Virus and
42 Risk for Venous Thromboembolism. *Clin Appl Thromb Hemost.* 2019;25.
43 doi:10.1177/1076029618821184

1 **Figure legends**

2 Figure 1: Exclusion Criteria for RNA and Coronaviruses.

3 Figure 2: Inflammatory Response-Induced Coagulopathy in SARS-CoV-2 Infection

4

ACCEPTED MANUSCRIPT

Table 1 Study Characteristics of Reported Skin Manifestations in patients infected with SARS-CoV-2

Author	Sample size	Erythematous/ Maculopapular/ Morbilliform (n, %)	Papulovesicular/ Varicella like lesions (n, %)	Petechiae/ Purpuric/ Ecchymosis Vasculitis (n, %)	Urticarial (n, %)	Chilblain lesions (CLL)(n, %)	Livedo Reticularis/ Racemosa (n, %)	Other (n, %)
Ghafoor et al. 2022 ⁵⁶	102	27 (26.5)	15 (14.7)	27 (26.5)	10 (9.8)	-	-	-
Waqas et al. 2006 ⁵⁷	6	-	-	-	-	-	6 (100)	-
Hasbani et al. 2021 ⁵⁸	1	-	-	1 (100)	-	-	-	-
Fujimoto et al. 2021 ⁵⁹	1	1 (100)	-	-	-	-	-	-
Shenker et al. 2020 ⁶⁰	1	-	-	1 (100)	-	-	-	-
Silva et al. 2020 ⁶¹	1	-	-	-	-	1 (100)	-	-
Levraut et al. 2021 ⁶²	1	-	-	1 (100)	-	-	-	-
Ciccarese et al. 2021 ⁶³	1	1 (100)	-	1 (100)	-	-	-	-
Karaca et al. 2020 ⁶⁴	1	1 (100)	-	-	-	-	-	-
Wollina 2020 ⁶⁵	1	-	-	1 (100)	-	-	-	-

Zulfiqar et al. 2020 ⁶⁶	1	-	-	1 (100)	-	-	-	-	-
Maestro et al. 2020 ⁶⁷	75	4 (5.3)	1 (1.3)	-	2 (2.7)	6 (8.0)	1 (1.3)	-	-
Fulgencio-Barbarin et al. 2020 ⁶⁸	1	-	-	-	-	-	-	-	-
Ghimire et al. 2021 ⁶⁹	1	1	-	-	-	-	-	-	-
Morales et al. 2020 ⁷⁰	1	-	-	-	-	-	-	-	Phlegmasia cerulea dolens, 1 (100)
Berrebi et al. 2021 ⁷¹	1	-	-	-	1 (100)	-	-	-	-
Calton et al. 2021 ⁷²	1	-	-	-	-	1 (100)	-	-	-
Phamduy et al. 2021 ⁷³	1	1 (100)	-	-	-	-	-	-	-
Capoferri et al. 2022 ⁷⁴	1	-	-	-	-	-	1 (100)	1 (100)	Oral ulcer, 1 (100)

Bibbo 2021 ⁷⁵	1	-	-	-	-	-	-	-	Necrosis/clear hemorrhagic bullae, 1 (100)
Gaspar et al. 2022 ⁷⁶	6	-	-	-	-	-	-	-	Unspecified skin rash, 6 (100)
Novara et al. 2020 ⁷⁷	1	-	-	-	-	-	-	-	Acral cyanosis progressing to gangrene, 1 (100)

Demissie et al. 2020 ⁷⁸	1	1 (100)	-	-	-	-	-	-	Mucocutaneous inflammation, 1 (100)
Sachdeva et al. 2020 ⁷⁵	45	26 (57.8)	4 (8.9)	1 (2.2)	8 (1.8)	3 (6.7)	5 (11.1)	-	-
Paparella et al. 2022 ⁷⁹	1	-	-	-	-	1 (100)	-	-	-
Colonna et al. 2022 ⁸⁰	1	-	-	-	-	1 (100)	-	-	-
Mascitti et al. 2021 ⁸¹	2756	-	-	-	-	1082 (39.3)	-	-	-
Gooch et al. 2021 ⁸²	1	1 (100)	-	-	-	-	-	-	-
Ocampo-Candiani et al. 2021 ⁸³	347	72 (20.7)	61 (17.6)	39 (11.2)	72 (20.7)	27 (7.8)	97 (28)	pityriasis rosea-like lesions, 15 (4)	-
Brancaccio et al. 2021 ⁸⁴	7	-	-	-	-	3 (42.9)	-	-	-

Larenas-Linnemann et al. 2021 ⁸⁵	6	1 (16.7)	1 (16.7)	-	1 (16.7)	1 (16.7)	-	EM, 1(16.7); KD, 1(16.7)
Vázquez-Osorio et al. 2021 ⁸⁶	2	-	-	-	-	2 (100)	-	-
Jacquin-Porretaz et al. 2021 ⁸⁷	12	2 (16.7)	2 (16.7)	-	3 (25)	-	1 (8.3)	Photo distributed rash, 1 (8.3)
Marzano et al. 2021 ¹⁷	200	48 (24)	29 (14.5)	13 (6.5)	19 (9.5)	46 (23)	4 (2)	-
Widysanto et al. 2021 ⁸⁸	1	-	-	1 (100)	-	-	-	-
Rubin et al. 2021 ⁸⁹	1	-	-	-	-	1 (100)	-	-
Andina et al. 2021 ⁹⁰	1	-	-	1 (100)	-	-	-	-
Fertitta et al. 2021 ⁹¹	1	-	-	-	-	1 (100)	-	-
Gambichler et al. 2021 ⁹²	1	-	-	-	-	1 (100)	-	-
Andina et al. 2020 ⁹³	1	-	-	-	-	1 (100)	-	-

García-Lara et al. 2020 ⁹⁴	25	-	-	-	-	-	25 (100)	-	-
Landa et al. 2020 ⁹⁵	2	-	-	-	-	-	2 (100)	-	-
Galván Casas et al. 2020 ²¹	375	176 (47)	34 (9)	-	71 (19)	-	-	23 (6.1)	-
Total	3994 (100)	363.3 (9.1)	147 (3.7)	87 (2.2)	187 (4.7)	1205 (30.2)	138 (3.5)	29 (0.7)	

EM- Erythema Multiform, KD- Kawasaki Disease

Table 2: Skin Finding by RNA Virus Families

Viral Family (N=Sample Size)	Characteristics and Key Features	Disease (n)	Erythematous/ Maculopapular/ Morbilliform n,(%)	Papulovesicular n,(%)	Petechiae/ Purpuric Vasculitis n,(%)	Facial Rash n,(%)	Unspecified n,(%)	Other n,(%)
Bunyaviridae (642) ^{55,96-102}	Negative-sense segmented.	Brucellosis (52)	-	-	3 (5.8)	-	18 (34.6)	-

	<p>Enveloped.</p> <p>Transmitted through arthropod vectors.</p> <p>Cause diseases such as hantavirus pulmonary syndrome, Crimean-Congo hemorrhagic fever, and Rift Valley fever.</p>	<p>Crimean Congo Virus (479)</p>	<p>23 (4.8)</p>	<p>-</p>	<p>143 (29.9)</p>	<p>128 (26.7)</p>	<p>37 (7.7)</p>	<p>Multiple Skin Findings, 60 (12.5) Skin eruption, 21 (4.4) Hematoma, 2 (0.4)</p>
		<p>Hemorrhagic Fever Renal Syndrome (HFRS) (34)</p>	<p>22 (64.7)</p>	<p>-</p>	<p>24 (70.6)</p>	<p>-</p>	<p>-</p>	<p>-</p>

		<p>Phleboviral Hemorrhagic Fever (HYSHF) (34)</p> <p>Severe fever with thrombocytopenia syndrome (43)</p> <p>Dengue (1,769)</p>	<p>14 (41.2)</p> <p>-</p> <p>-</p> <p>83 (4.7)</p>	<p>-</p> <p>-</p> <p>-</p> <p>-</p>	<p>9 (26.5)</p> <p>9 (20.9)</p> <p>610 (34.5)</p>	<p>-</p> <p>-</p> <p>-</p>	<p>-</p> <p>-</p> <p>-</p>	<p>-</p> <p>-</p> <p>Non specified rash 535 (30.2) Facial rash 51(2.9) Itching 166</p>
<p>Flaviviridae (1,769)¹⁰³⁻¹¹³</p>	<p>Positive-sense single-stranded. Enveloped. Transmitted by arthropod vectors</p>							

	<p>like mosquitoes and ticks.</p> <p>Cause diseases such as hepatitis C, dengue fever, Zika virus infection, and yellow fever.</p>		<p>1 (1.0)</p>		<p>7 (6.7)</p>	<p>-</p>	<p>-</p>	<p>(9.4)</p> <p>Cold hands/feet 20 (1.1) Flushing 53 (3.0)</p>
<p>Orthomyxoviridae</p> <p>104^{34, 114-117}</p>	<p>Negative-sense segmented.</p> <p>Enveloped.</p> <p>Responsible for influenza viruses, causing seasonal</p>	<p>Influenza (104)</p>	<p>1 (1.0)</p>	<p>-</p>	<p>7 (6.7)</p>	<p>-</p>	<p>-</p>	<p>Oral ulcer, 1 (1.0)</p>

<p>Paramyxoviridae 8¹⁷⁻¹²¹</p>	<p>epidemics and occasional pandemics. Includes Influenza A, B, and C.</p>	<p>Measles (5) Mumps (1) Parainfluenza and Respiratory Syncytial Virus (2)</p>	<p>1 (20.0)</p>	<p>-</p>	<p>3 (60.0)</p>	<p>-</p>	<p>-</p>	<p>Erythema elevatum diutinum, 1 (20.0)</p>
<p>Negative-sense single-stranded. Enveloped. Cause respiratory infections (measles, mumps), as well as other diseases. May also lead to</p>	<p>-</p>	<p>-</p>	<p>-</p>	<p>1</p>	<p>-</p>	<p>-</p>	<p>-</p>	<p>2 (100)</p>

<p>Picornaviridae 546¹²²⁻¹²⁸</p>	<p>syncytium formation. Members include paramyxoviruses and pneumoviruses.</p>	<p>Coxsackie A/B (321)</p>	<p>16 (4.9)</p>	<p>29 (9.0)</p>	<p>1 (3.1)</p>	<p>-</p>	<p>146 (45.5)</p>	<p>HFM, 99 (30.8) Oral ulcer, 146 (45.5) Facial involvement, 13 (4.0) Pain/itching, 4 (1.2) EM, 3 (0.9)</p>
--	--	----------------------------	-----------------	-----------------	----------------	----------	-------------------	---

Retroviridae 381 ¹²⁹⁻¹³⁷	Members include enteroviruses, rhinoviruses, and hepatoviruses.	Echovirus (215)	-	-	2 (0.9)	-	78 (36.3)	Herpangina, 3 (1.4) HFM 6, (2.8)
		Hepatitis A (1) Hepatitis B (2) Hepatitis C (321)	1 (100) 1 (50) 61 (19.0)	- - -	1 (100) 1 (50) -	- - -	- - -	Unspecified skin rash, 55 (17.1) Psoriasis, 1 (0.1) PCT, 3 (0.9) LP, 3 (0.9)
	Positive-sense single-stranded RNA viruses that are reverse-transcribed into DNA. Enveloped. Includes human immunodeficiency	HIV (44)	-	-	14 (31.8)	-	-	-
		HTLV II	-	-	2 (14.3)	-	-	-

	virus (HIV), causing AIDS, and other retroviruses. Key feature: integration into host genome.	(14)						
Togaviridae 4913 ¹³⁸⁻¹⁴¹	Positive-sense single-stranded. Enveloped. Transmitted by arthropod vectors. Include alphaviruses	Chikungunya (495)	27 (5.9)	-	-	-	63 (12.7)	Oral ulcer, 63 (7) Pain/itching, 286 (57.8)
		Rubella (4387)	4116 (93.8)	104 (2.4)	19 (0.4)	-	-	-
		Zika (31)	17 (54.8)	-	-	-	-	-

	(e.g., Chikungunya virus) and rubiviruses (e.g., rubella virus).	8362	4376 (52.3)	133 (1.6)	887 (10.6)	399 (4.8)	949 (11.3)	
Total								

(PCT)= Porphyria cutaneous tarda, (LP)-Lichen Planus

CPD Questions

Learning Objective: To gain up-to-date knowledge about the latest documentation of vascular cutaneous manifestations associated with RNA viruses.

Question 1. What percentage of COVID infected patients present with dermatologic symptoms?

- (a) 5%
- (b) 10%
- (c) 20%
- (d) 30%
- (e) 40%

Question 2. What are the two main categories of COVID-19 cutaneous manifestations?

- (a) Inflammatory and autoimmune reactions
- (b) Vascular and hematologic abnormalities
- (c) Allergic and immunological responses
- (d) Inflammatory and vascular reactions
- (e) All of the above

Question 3. Which of the following statements about SARS-CoV-2's impact on the vascular system is true?

- (a) SARS-CoV-2 only affects arterial smooth muscle cells.
- (b) The binding of SARS-CoV-2 to ACE-2 downregulates the levels of angiotensinogen II (Ang II) causing oxidative stress, endothelial damage, and thrombosis.
- (c) ACE-2 is the functional receptor utilized by SARS-CoV-2
- (d) SARS-CoV-2 binding to ACE-2 can lead to an increase in Ang II levels, causing oxidative stress, endothelial damage, and thrombosis.
- (e) Both (c) and (d)

Question 4. In light of their shared respiratory droplet transmission method with the Coronaviridae family, which RNA virus family demonstrates a distinct absence of vascular cutaneous manifestations?

- (a) Coronaviridae
- (b) Flaviviridae
- (c) Rhabdoviridae
- (d) Orthomyxoviridae
- (e) Bunyaviridae

Question 5. A virus belonging to which of the following families causes pedal edema with an onset timing similar to that of COVID-19?

- (a) Picornaviridae
- (b) Flaviviridae
- (c) Bunyaviridae
- (d) Retroviridae
- (e) Togaviridae




Figure 1
144x185 mm (x DPI)

ACCEPTED MANUSCRIPT




Figure 2
165x151 mm (x DPI)